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Abstract
Background: In addition to cytotoxic mechanisms directly impacting neurons, b-amyloid (Ab)-induced glial
activation also promotes release of proinflammatory molecules that may self-perpetuate reactive gliosis and
damage neighbouring neurons, thus amplifying neuropathological lesions occurring in Alzheimer’s disease (AD).
Palmitoylethanolamide (PEA) has been studied extensively for its anti-inflammatory, analgesic, antiepileptic and
neuroprotective effects. PEA is a lipid messenger isolated from mammalian and vegetable tissues that mimics
several endocannabinoid-driven actions, even though it does not bind to cannabinoid receptors. Some of its
pharmacological properties are considered to be dependent on the expression of peroxisome proliferator-activated
receptors-a (PPARa).
Findings: In the present study, we evaluated the effect of PEA on astrocyte activation and neuronal loss in models
of Ab neurotoxicity. To this purpose, primary rat mixed neuroglial co-cultures and organotypic hippocampal slices
were challenged with Ab1-42 and treated with PEA in the presence or absence of MK886 or GW9662, which are
selective PPARa and PPARg antagonists, respectively. The results indicate that PEA is able to blunt Ab-induced
astrocyte activation and, subsequently, to improve neuronal survival through selective PPARa activation. The data
from organotypic cultures confirm that PEA anti-inflammatory properties implicate PPARa mediation and reveal
that the reduction of reactive gliosis subsequently induces a marked rebound neuroprotective effect on neurons.
Conclusions: In line with our previous observations, the results of this study show that PEA treatment results in
decreased numbers of infiltrating astrocytes during Ab challenge, resulting in significant neuroprotection. PEA
could thus represent a promising pharmacological tool because it is able to reduce Ab-evoked neuroinflammation
and attenuate its neurodegenerative consequences.
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Background
Alzheimer’s disease (AD) is a progressive neurodegen-
erative disorder clinically characterized by impairment
of cognitive functions and memory loss. Its two core
neuropathological hallmarks are deposits of b-amyloid
(Ab) fibrils in senile plaques (SPs) and accumulation of
hyperphosphorylated tau protein filaments in
neurofibrillary tangles (NFTs) [1]. In vitro and in vivo
findings have demonstrated that Ab fragments promote
a marked neuroinflammatory response that accounts for
the synthesis of different cytokines and proinflammatory
mediators [2]. After their release, proinflammatory sig-
nalling molecules act in an autocrine manner to self-
perpetuate reactive gliosis and in a paracrine manner to
kill neighbouring neurons, thus amplifying neuropatho-
logical damage [3]. Once considered a marginal event,
appreciation of the role of inflammation in AD patho-
genesis has increased rapidly in recent years [4,5]. It is
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may contribute independently to neural dysfunction and
cell death [6]. The relevance of reactive gliosis now
prompts a reconsideration of the perceived relationship
between neuroinflammation and neurodegeneration,
making it clear that one is not simply a culmination of
the other and that both, mutually, have a crucial impact
on the course of AD. On the basis of these considera-
tions, it is now appropriate that compounds able to
modulate astrocyte activation be considered as novel
therapeutic tools. Among these molecules, palmitoy-
lethanolamide (PEA) has attracted a lot of attention for
its numerous pharmacological properties and its very
low toxicity [7]. PEA, a naturally occurring amide of
ethanolamide and palmitic acid, is a lipid messenger
that mimics several endocannabinoid-driven actions,
even though it does not bind to cannabinoid receptors.
Converging evidence indicates that endogenous N-acy-
lethanolamine compounds, including PEA, bind with
relatively high affinity to peroxisome proliferator-acti-
vated receptor a (PPARa), and they are now recognized
among their physiological ligands [8,9]. PPARs are a
family of ligand-dependent nuclear hormone receptor
transcription factors. To date, three isoforms have been
identified (PPARa; PPARb, also called δ; and PPARg),
and all three isotypes are expressed in the brain with
different distributions. Although PPARb/δ is almost ubi-
quitously expressed, PPARa and g are localized to more
restricted brain areas. The role of PPARs in the brain
has, for the most part, been related to lipid metabolism;
however, these receptors have also been implicated in
neural cell differentiation and death as well as in inflam-
mation and neurodegeneration [10,11]. PPARs stimulate
gene expression by binding to peroxisome-proliferator
response elements (PPREs) that are present in promoter
regions of the target genes. In the absence of ligands,
the heterodimers physically associate with corepressors
and suppress gene transcription [12]. Upon ligand bind-
ing, the coactivators replace corepressors and activate
gene expression [13].
PEA is abundant in the central nervous system (CNS),
and it is conspicuously produced by glial cells [14-16].
PEA has been studied extensively for its anti-inflamma-
tory and neuroprotective effects, mainly in models of
peripheral neuropathies [17,18]. Some of its properties
have been considered to be mediated by PPARa tran-
scriptional activity [19,20]. Both PPARa and PEA are
clearly detected in the CNS, and their expression may
show large changes during pathological conditions
[21,22]. However, its physiological role and its pharma-
cological properties in the CNS remain, at present and
f o rt h em o s tp a r t ,u n c l e a r .O u rg r o u ph a sr e c e n t l y
demonstrated the ability of PEA to mitigate reactive
gliosis induced in primary rat astrocytes exposed to Ab
by interacting with PPARa [23].
On the basis of these considerations, the present study
was designed to confirm the effect of PEA on astrocyte
activation in the models that we used and to verify
whether its control of reactive gliosis leads to a
“rebound” protection on neurons. To this purpose, our
experiments were carried out using mixed neuroglia co-
cultures and hippocampal organotypic slices treated
with Ab in the presence or absence of PEA. In addition,
to define the molecular mechanisms responsible for the
observed effects induced by PEA, further experiments
were performed in the presence or absence of GW9662
and MK886, which are selective PPARg and PPARa
antagonists, respectively.
Methods
All experiments were performed in accordance with the
National Institutes of Health guidelines for the care and
use of laboratory animals and those of the Italian Minis-
try of Health (DL 116/92), and they were approved by
the Institutional Animal Care and Use Committee at
our institution.
Cell cultures and treatments
Rat primary astroglial cultures were obtained from new-
born Sprague-Dawley rats (1 or 2 days old) according to
the procedure described by Vairano et al. [24]. Brain
homogenates were mechanically processed to obtain sin-
gle cells that were seeded in 75-cm
2 flasks at a density
of 3 × 10
6 cells/flask with 15 ml of culture medium
(DMEM, 5% inactivated foetal bovine serum, 100 IU/ml
penicillin and 100 μg/ml streptomycin; all from Sigma-
Aldrich, Milan, Italy) and incubated at 37°C in a humi-
dified atmosphere containing 5% CO2. The culture med-
ium was replaced after 24 hours and again twice weekly
until astrocytes were grown to form a monolayer firmly
attached to the bottom of the flask (7 or 8 days after
dissection). At cell confluence, flasks were vigorously
shaken to separate astrocytes (which remained adherent
in the bottom of the flasks) from microglia and oligo-
dendrocytes (which floated on the supernatant). The
same process was repeated after about 1 week of cul-
ture. Collected astrocytes were seeded onto 10-cm-dia-
meter Petri dishes at a density of 1 × 10
6 cells/dish. The
purity of the cells in culture was tested with monoclonal
anti-glial fibrillary acidic protein (GFAP), and only cul-
tures with more than 95% GFAP-positive cells were
used for the experiments. The 5% of nonastrocyte cells
were microglia and oligodendrocytes.
Cultures of rat primary neurons were prepared from
embryonic day 18 Sprague-Dawley rats according to the
method described by Antonelli et al. [25]. Pregnant
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uterus containing the embryos was removed from the
adult rat. The embryos were decapitated, and the brain
was removed from the cranium. Removed cortices were
dissected free of meninges and dissociated in 0.025%
(wt/vol) trypsin. The tissue fragments were dissociated
mechanically through a glass Pasteur pipette. The cells
were cultured in Neurobasal Medium supplemented
with 0.1 mM glutamine, 10 μg/ml gentamicin and 2%
B27 (all purchased from Invitrogen/Life Technologies,
Monza, Italy). Cells were grown at 37°C in a humidified
atmosphere containing 5% CO2. The cultures were left
to grow for 1 week to reach a stage similar to the cells
prepared from newborn rat pups.
Mature astrocytes and neurons were counted by direct
microscopic counting using trypan blue (Sigma-Aldrich)
staining in a Bürker chamber and co-cultured at a ratio
of approximately 10:1. Cells pelleted and resuspended in
Neurobasal Medium supplemented with 0.1 mM gluta-
mine, 10 μg/ml gentamicin and 2% B27. Next these
mixed neuroglia co-cultures were plated on glass slide
chambers coated with poly-D-lysine (BD Biosciences,
Buccinasco, Italy) at a density of 2.5 × 10
4 cells/chamber
and cultured at 37°C in a humidified atmosphere con-
taining 5% CO2 for 24 hours before treatment.
Mixed neuroglial co-cultures were treated with 1 μg/
ml Ab1-42 (Tocris Bioscience, Bristol, UK) in the pre-
sence or absence of the following substances: PEA (0.1
μM), MK886 (3 μM), the selective PPARa antagonist,
and GW9662 (9 nM), the selective PPARg antagonist
(all purchased from Tocris Bioscience). After 24 hours
of treatment, cells were processed for analyses. The con-
centration of the substances was chosen according to
our previous results [23]. No significant variation from
control was observed when PEA, MK886 or GW9662
was given alone (data not shown).
Preparation of organotypic cultures and treatments
Organotypic hippocampal slice cultures were prepared
according to the method described by Pellegrini-Giam-
pietro et al. [26]. Briefly, 7-day-old Sprague-Dawley rats
were killed by decapitation, and the extracted brains
were transversely cut using a vibratome (Microm HM
650 V; Microm International GmbH Part of Thermo
Fisher Scientific Walldorf, Germany) to obtain 400-μm
coronal sections containing the hippocampi. These
slides were placed onto semiporous inserts (4 μm in dia-
meter; Millipore, Vimodrone, Italy) and cultured in 6-
cm-diameter Petri dishes with 1.2 ml of DMEM supple-
mented with 25% Hank’s Balanced Salt Solution (Invi-
trogen/Life Technologies), 25% heat-inactivated horse
serum (Sigma-Aldrich), 20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid and 1.5% penicillin-strep-
tomycin at 37°C in a humidified atmosphere containing
5% CO2. The culture medium was refreshed upon
necessity.
On day 21 of culturing, organotypic hippocampal slide
cultures were treated with 1 μg/ml Ab1-42 in the pre-
sence or absence of the following substances: PEA (0.1
μM), MK886 (3 μM) or GW9662 (9 nM), with the latter
two being selective PPARa and PPARg antagonists,
respectively. Twenty four hours after the treatments,
sections were washed twice with 1 × PBS and fixed
overnight at 4°C with 4% paraformaldehyde in 1 × PBS,
then slices were gently removed from inserts and pro-
cessed for morphological and immunofluorescence
experiments.
Nissl staining
Mounted sections were sequentially dipped in different
alcohol solutions of decreasing concentration to remove
lipids from the tissue, then they were stained with 2%
cresyl violet solution for 5 minutes and finally brain sec-
tions were dehydrated with a series of baths of increas-
ing alcohol concentrations. Sections were observed
through a microscope (Nikon Eclipse 80i; Nikon Instru-
ments Europe, Kingston upon Thames, UK). Corre-
sponding pictures were captured at 2 × magnification
using a high-resolution digital camera (Nikon Digital
Sight DS-U1; Nikon Instruments Europe) and analyzed
using NIS-Elements software (Nikon Instruments
Europe).
Immunofluorescence
Both mixed neuroglial and glass-mounted organotypic
cultures were washed with 1 × PBS and fixed with 4%
paraformaldehyde in 1 × PBS. Afterwards samples were
blocked in 10% albumin bovine serum 0.1% Triton-PBS
solution for 90 minutes, then they were incubated for 1
hour with a 10% albumin bovine serum/0.1% Triton-
PBS solution containing the following antibodies: anti-
GFAP (1:500 dilution; Abcam plc, Cambridge, UK) and
anti-microtubule-associated protein 2 (MAP2) (1:200,
Novus Biologicals, Milan, Italy). Finally, samples were
incubated for 1 hour in the dark with the proper sec-
ondary antibodies: fluorescein isothiocyanate-conjugated
anti-rabbit at 1:100 dilution or Texas Red-conjugated
anti-mouse at 1:64 dilution (both from Abcam plc),
respectively. Nuclei were stained with Hoechst at
1:5,000 dilution (Sigma-Aldrich, St. Louis, MO, USA)
added to the secondary antibody solution.
Pictures were taken using a camera (Nikon Digital
Sight DS-U1) connected to a microscope (Nikon Eclipse
80i; Nikon Instruments Europe) provided with the
proper fluorescence filters. Slides were analyzed with a
microscope (Nikon Eclipse 80i), and images were cap-
tured at 10 × and 20 × magnification with a high-resolu-
tion digital camera (NikonD i g i t a lS i g h tD S - U 1 ) .
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specific digital system (NIS-Element Basic Research ver-
sion 2.30 software).
Statistical analysis
Results are expressed as means ± SEM of the experi-
ments. Statistical analysis was performed using para-
metric one-way analysis of variance, and multiple
comparisons were performed using the Bonferroni test
with the GraphPad InStat statistical software program
(GraphPad Software, La Jolla, CA, USA). P <0 . 0 5w a s
considered significant.
Results and discussion
The classical amyloid cascade hypothesis claims that an
imbalance between the production and degradation or
Figure 1 PEA inhibits astroglial proliferation and reduces neuronal loss in mixed neuroglia co-cultures exposed to Ab.A b-challenged (1
μg/ml) astrocyte/neuron mixed cultures were treated with PEA (0.1 μM) in the presence of the selective PPARg antagonist (GW9662, 9 nM) or
the selective PPARa antagonist (MK886, 3 μM). After 24 hours of treatment, cells were processed for analyses. (A) Immunofluorescence
photomicrographs showing the effect of the treatments on astrocyte proliferation and neuronal loss, as determined by immunostaining for
GFAP (green) and MAP2 (red), respectively. Arrows indicate chromatin condensation in nuclei stained with Hoechst dye (blue) as markers of
apoptotic events. Scale bar: 10 μm. (B) Relative quantification of GFAP-positive cell number as a count of astrocyte proliferation. (C) Apoptotic
events detected on MAP2-expressing cells as an indication of neuronal death. For (B) and (C), the average value was determined by counting
cells in at least nine microscopic fields for each treatment. Results are presented as means ± SEM of three separate experiments. Statistical
analysis was performed using parametric one-way analysis of variance, and multiple comparisons were performed using the Bonferroni test. ***P
< 0.001 vs. unstimulated cells,
∘∘P < 0.01 and
∘P < 0.05 vs. Ab-stimulated cultures.
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event in AD neuropathology, leading to synaptic damage
and neuronal death. In the current investigation, experi-
ments were performed utilizing models that, in many
respects, although not fully, reflect conditions that occur
in the brain in AD. The results of the present study
demonstrate that PEA treatment causes a significant,
marked reduction of astrocyte activation and a parallel
neuronal protection in both mixed neuroglial and orga-
notypic hippocampal cultures.
We have previously demonstrated that PEA strongly
downregulates reactive gliosis by reducing
proinflammatory molecules and cytokine release through
the inhibition of NF-B in rat astrocytes [23]. The pre-
sent findings extend our knowledge of PEA pharmacol-
ogy. In particular, they indicate that such modulation of
astrocyte function accounts for a rebound neuroprotec-
tion. Indeed, data from mixed neuroglial co-cultures
indicate that PEA treatment results in a massive reduc-
tion (in comparison with the Ab group) in astrocyte
number, as shown by the reduction in the GFAP-immu-
nopositive cells (Figures 1A and 1B). Consequently, such
an effect is accompanied by a significant decrease in the
number of apoptotic nuclei in MAP2-positive neurons
Figure 2 PEA decreases astrocyte activation in organotypic cultures of rat hippocampi and rescues neuronal CA3 damage caused by
Ab challenge.A b-challenged (1 μg/ml) slices of rat hippocampi were treated for 24 hours with PEA (0.1 μM) in the presence of the selective
PPARg antagonist (GW9662, 9 nM) or the selective PPARa antagonist (MK886, 3 μM). (A) Nissl staining showing the effect of treatment on the
morphology of organotypic hippocampal slices. Scale bar: 80 μm. Ab caused a marked neuronal loss, mainly in the CA3 region of hippocampus,
as highlighted by arrows. PEA was able to reverse this effect. (B) Representative photomicrographs of the CA3 region showing the results of
immunofluorescence experiments aimed at investigating the effect of treatments on astrocyte activation and neuronal loss, as determined by
immunostaining for GFAP (green) and MAP2 (red) alone or merged, respectively. Nuclei were stained with Hoechst (blue). Scale bar: 10 μm.
Arrows in the photomicrographs indicate astrocyte infiltration events and apoptotic condensation in the nuclei of adjacent neurons. (C) Relative
quantification of GFAP-positive cell number as a count of astrocyte proliferation. (D) Apoptotic events detected on MAP2-expressing cells as an
indication of neuronal death. For (C) and (D), the average value was determined by counting cells in at least five microscopic fields for each
treatment. Results are presented as means ± SEM of four separate experiments. At least four slices from each experimental group were observed
for each experiment. Statistical analysis was performed using parametric one-way analysis of variance, and multiple comparisons were performed
using the Bonferroni test. ***P < 0.001 and *P < 0.05 vs. control;
∘∘P < 0.01 and
∘P < 0.05 vs. Ab-challenge slices.
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crographs indicate that the PEA antigliosis and neuro-
protective effects are inescapably due to PPARa
involvement because MK886, the selective PPARa
antagonist, almost completely abolishes the PEA effects,
whereas GW9662, the selective PPARg antagonist, does
not show any detectable influence.
General overview of Nissl-stained hippocampi indi-
cates that Ab treatment results in a depletion of CA3
pyramidal neurons compared to controls. PEA treatment
rescues the integrity of this area, and, in agreement with
the above-described in vitro results, its neuroprotective
effect appears to be dependent on PPARa interaction
(Figure 2A).
Furthermore, immunofluorescence analysis of the CA3
area of the same hippocampi reveals a marked activation
and an infiltration of astrocytes after Ab treatment (Fig-
ure 2). In fact, we observed an evident increase in the
size and number of GFAP-immunopositive cells that
paralleled a higher number of apoptotic nuclei in
MAP2-positive neurons (Figures 2B through 2D). Such
effects were counteracted by treatment with PEA, and
we also observed in these experiments that its action
was strongly dependent on the selective activation of
PPARa (Figure 2B).
In conclusion, our data provide evidence that PEA
blunts reactive gliosis and subsequently prevents neuro-
nal damage in models of Ab neurotoxicity. These
observed effects are strictly dependent on the activation
of PPARa. In addition, although some authors have
hypothesized that a number of pharmacological actions
of PEA could be mediated by modifications occurring in
the endocannabinoid system, no significant changes
were observed in either 2-arachidonoylglycerol or ana-
ndamide levels in our experimental conditions (data not
shown). This assumption further supports a key role for
PPARa as a molecular target at which PEA acts to miti-
gate the toxic effects induced by Ab.
The relevance of these results resides in the hypoth-
esis that pharmacological attenuation of excessive and
prolonged reactive gliosis may serve as an innovative
strategy for therapies aimed at ameliorating the course
of AD. There is an urgent need for new molecules that
will affect different pathological pathways, all converging
on progressive neurological decline. Our data suggest
that PEA is capable of profoundly reducing reactive
astrogliosis and of guaranteeing neuronal protection in
Ab-induced neuroinflammatory and neurodegenerative
events.
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